Navigation Links
CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts
Date:5/1/2008

Emerging spinal company continues to focus on unmet needs of the lumbar

disc

MINNEAPOLIS, May 1 /PRNewswire/ -- CoreSpine Technologies, LLC, an emerging spinal device company announced today the expansion of its platform technology for spinal implant procedures to include an application for minimally invasive fusion.

The development of CoreSpine's Technologies' initial prototype concentrated on generating a complete and selective nucleus removal device. The technology was recently expanded to incorporate a cartilage removal device for endplate preparation. The importance of the company's proprietary technology is elevated as spinal implants and therapies begin to require more effective nucleus removal and endplate preparation through limited access.

There is a strong momentum within the spine industry to move in the direction of products that support tissue sparing, motion preserving and minimally invasive techniques. The goal of CoreSpine's proprietary technology is to universally meet the specific preparation requirements of both current and emerging implant technologies.

Initial data to support the technology's enhanced ability over existing options will be presented at the Spine Arthroplasty Society's 8th annual meeting in Miami. The presentation by John Sherman, M.D., Medical Director for CoreSpine will occur on Friday, May 9th at 3:09 p.m. The presentation consists of initial data collected using CoreSpine's prototype for nucleus removal. Additional information will be available in CoreSpine's booth, #327, during the SAS meeting.

About CoreSpine Technologies, LLC

CoreSpine Technologies, LLC is headquartered in Minneapolis, MN. The company is focused on developing a platform technology to produce advanced surgical devices for the complete or selective removal of material from the lumbar disc space. The devices are intended for use in the rapidly emerging and changing fields of
'/>"/>

SOURCE CoreSpine Technologies, LLC
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
2. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
3. Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
4. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
5. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
6. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
7. Senesco Technologies Initiates Preclinical Studies for Cancer Target
8. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
9. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
10. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3JAG Media Holdings Inc Amends Articles of Incorporation 58781 1JAG Media Holdings Inc Amends Articles of Incorporation 58781 2Vermillion Announces Return of Eric Fung M D Ph D 14338 1Vermillion Announces Return of Eric Fung M D Ph D 14338 2Vermillion Announces Return of Eric Fung M D Ph D 14338 3Hamon Tower Features Critical Care Advances Potential for Reduced Costs 5195 1Hamon Tower Features Critical Care Advances Potential for Reduced Costs 5195 2